A derivative of the D5 monoclonal antibody that targets the gp41 N-heptad repeat of HIV-1 with broad tier-2 neutralizing activity
A. A. Rubio, M. V. Filsinger Interrante, B. N. Bell, C. L. Brown, C. C. LaBranche, D. C. Montefiori, P. S. Kim
This paper describes the engineering of a D5 monoclonal antibody variant, D5_AR, which shows enhanced neutralizing activity against tier-2 HIV-1 strains and improved potency in cells expressing FcγRI.
bioRxiv · Oct 23, 2020Immunology